Literature DB >> 26756000

Prevalence of Ureaplasma urealyticum and Mycoplasma hominis in High Vaginal Swab Samples of Infertile Females.

Mehri Seifoleslami1, Aghdas Safari2, Maryam Khayyat Khameneie2.   

Abstract

BACKGROUND: Mycoplasma hominis and Ureaplasma urealyticum are important causative agents of vaginitis, cervicitis, postpartum sepsis, reproductive infections and infertility in both males and females.
OBJECTIVES: According to the uncertain prevalence of U. urealyticum and M. hominis in Iranian infertile females, the present study was carried out to determine the prevalence of U. urealyticum and M. hominis in high vaginal swab samples of fertile and infertile females. PATIENTS AND METHODS: A total of 350 high vaginal swab specimens were taken from fertile and infertile females. Samples were cultured and those that were positive for bacteria were subjected to the polymerase chain reaction (PCR) for further confirmation.
RESULTS: Of the 350 collected samples, eleven were positive for M. hominis (3.14%), fifteen were positive for U. urealyticum (4.28%) and five were positive for both of them (1.42%). Prevalence of U. urealyticum and M. hominis in the high vaginal parts of infertile females was higher than fertile females (P < 0.05). The results of traditional method were also confirmed, using the PCR amplification of urease gene of U. urealyticum and 16SrRNA gene of the M. hominis. Ureaplasma urealyticum and M. hominis had a higher prevalence in the high vaginal samples collected during the summer season.
CONCLUSIONS: Considerable prevalence of M. hominis and U. urealyticum in the high vaginal swab samples of infertile females compared to the low prevalence in fertile females may suggest that these two pathogens can be cause infertility. Application of the PCR method is recommended for rapid and sensitive detection of M. hominis and U. urealyticum in high vaginal swab samples.

Entities:  

Keywords:  Female; Infertility; Iran; Mycoplasma hominis; Prevalence; Ureaplasma urealyticum

Year:  2015        PMID: 26756000      PMCID: PMC4706991          DOI: 10.5812/ircmj.16823

Source DB:  PubMed          Journal:  Iran Red Crescent Med J        ISSN: 2074-1804            Impact factor:   0.611


1. Background

One of the main issues dealt by gynecologists is infertility. Infertility is considered when couples have been trying to become pregnant with frequent intercourse for at least a year with no success (1-4). Documented data revealed that approximately 72.4 million couples are infertile (4). The main reasons for 25% of infertility cases are still unknown (1-4). The majority of females with infertility problems are afflicted with inflammatory changes of the oviduct or surrounding peritoneum. Most of these alterations result from infections (5). Mycoplasma hominis and Ureaplasma urealyticum have been isolated from genital mucosal surfaces, vagina and cervical parts of females (6, 7). They have also been isolated from cases of genital infections including both males and females (8). Ureaplasma urealyticum is a major cause of non-chlamydial and non-gonococcal urethritis, chorioamnionitis, acute prostatitis, vaginitis, cervicitis, preterm delivery and sepsis (8, 9). Mycoplasma hominis is often associated with vaginitis, cervicitis, postpartum sepsis, pyelonephritis, preterm labor and premature birth (10, 11). Bacterial vaginosis is strongly implicated in female infertility and it probably is an underestimated cause of unexplained infertility. It was also documented that screening and treatment of bacterial vaginosis during the course of infertility treatment increased the rate of pregnancy (12). Therefore, it is important to know the exact prevalence rate of infectious agents that cause vaginitis in infertile women. In keeping with this, safe, rapid, accurate and sensitive diagnosis of these infectious agents can help medical practitioners reduce the risk of vaginitis and infertility.

2. Objectives

The exact prevalence and epidemiology of M. hominis and U. urealyticum is still unknown in Iran. Therefore, the present investigation was carried out in order to determine the prevalence rate of M. hominis and U. urealyticum in high vaginal swab samples of infertile females, who had been referred to Iranian sterility and infertility hospitals due to their infertility problems.

3. Patients and Methods

3.1. Ethical Issues

The present study was approved by the ethical committee of various infertility and sterility centers of Iran. The authors made every attempt to protect the life, health, dignity, integrity, and rights to self-determination, privacy and confidentiality of the personal information of the studied females. We conformed to generally accepted scientific principles, based on a thorough knowledge of the scientific literature, other relevant sources of information, and adequate laboratories. All samples were taken from volunteers who were referred to various infertility and sterility hospitals of Iran.

3.2. Samples Collection

From October 2013 to October 2014, a total of 150 high vaginal swab specimens were taken from infertile females. Generally, a female who was not pregnant after a year of regular intercourse without prevention was defined as infertile. Vaginal specimens were collected from the ventral fornix without any contact with urine and external parts of the reproductive system using speculum and commercial sterile cotton-tipped swabs. All specimens were collected by an expert midwife. Two-hundred vaginal swab specimens were also collected from fertile females with no history of infertility.

3.3. Ureaplasma urealyticum and Mycoplasma hominis identification

In order to identify the bacteria, the method described by Bayraktar et al. (2010) (13) was used. Mycoplasma hominis and U. urealyticum were detected using a commercial kit, Mycoplasma IST-2 (BioMerieux, Marcy l’Etoile, France), according to the manufacturer’s instructions. The kit contained strips that gave information about the presence or absence of M. hominis and U. urealyticum. One strip was placed directly into R1 tubes (transport medium) and subsequently delivered to the clinical laboratory for the identification of both U. urealyticum and M. hominis. Swabs in the R1 transport medium were processed according to the manufacturer’s instructions. They were vortexed rapidly, and 3 mL of R1 was used to rehydrate the lyophilized growth medium R2 (provided in the Mycoplasma IST-2 kit). A mycoplasma IST strip, consisting of 22 wells, was then inoculated with the rehydrated R2 growth medium (55 mL per well, overlaid with two drops of mineral oil). From the R2 positive tube, 0.1 mL was also inoculated onto A7 Mycoplasma agar plates (BioMerieux, Marcy l’Etoile, France) and incubated at 37°C in an atmosphere of 5% CO2 for checking characteristic colony morphology. All media and the inoculated strip were incubated at 37°C in a CO2 incubator and observed for color changes, and the results were interpreted after 24 and 48 hours of incubation. Wells provided information on the presence or absence of M. hominis and U. urealyticum, with an estimate of the density of each organism (≥ 104 CFU). The A7 plates were examined with a microscope twice daily for up to five days for characteristic colonies. Colonies presenting a fried egg appearance suggested the presence of M. hominis, whereas colonies that were brown and tiny indicated the presence of U. urealyticum. Mycoplasma hominis ATCC 23114 and U. urealyticum ATCC 27618 strains were used as controls.

3.4. Polymerase Chain Reaction Confirmation of Ureaplasma urealyticum and Mycoplasma hominis

A PCR technique was used in order to detect U. urealyticum and M. hominis (14, 15). Total genomic DNA was extracted from the bacterial colonies using the commercial genomic DNA extraction kit (Fermentas, Germany), according to the manufacturer’s instructions. The DNA concentration was determined by measuring absorbance of the sample at 260 nm using a spectrophotometer (16). Table 1 shows the oligonucleotide primers, size of products and PCR conditions used for detection of U. urealyticum and M. hominis. The PCR amplification products (15 μL) were subjected to electrophoresis on 1.5% agarose gel in 1X Tris/Borate/EDTA (TBE) buffer at 80 V for 30 minutes, stained with SYBR Green. All runs included a negative DNA control consisting of PCR grade water, and strains of M. hominis ATCC 23114 and U. urealyticum ATCC 27618 were used as positive controls.
Table 1.

The Oligonucleotide Primers and the Polymerase Chain Reaction Programs Used for Amplification of Urease Gene of the Ureaplasma urealyticum and 16SrRNA gene of the Mycoplasma hominis (14,15)

Target GenePrimer Sequence (5’ - 3’)*PCR Product, bpPCR ProgramsPCR Volume, 50µL
Urease gene of the U. urealyticum 4291 cycle: 95 °C at 3 minutes; 30 cycle: 95 °C at 20 seconds; 58 °C at 40 seconds; 72 °C at 30 seconds.5 µL PCR buffer 10×;1.5 mM Mgcl2; 200 µM dNTP (Fermentas); 0.5 µM of each primers F & R; 1.25 U Taq DNA polymerase (Fermentas); 2.5 µL DNA template.
FACGACGT CCATAAGCAACT
RCAATCTGCTCGTGAAGTATTAC
16SrRNA gene of the M. hominis 3441 cycle: 95 °C at 3 minutes; 30 cycle: 95 °C at 20 seconds; 58 °C at 40 seconds; 72 °C at 30 seconds; 1 cycle: 72 °C at 8 minutes5 µL PCR buffer 10×;1.5 mM Mgcl2; 200 µM dNTP (Fermentas); 0.5 µM of each primers F & R; 1.25 U Taq DNA polymerase (Fermentas); 2.5 µL DNA template
FCAA TGG CTA ATG CCG GAT ACG C
RGGT ACC GTC AGT CTG CAA T

3.5. Statistical Analysis

Statistical analysis was performed using the SPSS version 16.0 software for significant relationships. The incidences of M. hominis and U. urealyticum in fertile and infertile cases were statistically analyzed. Statistical significance was regarded at a P value of < 0.05.

4. Results

A total of 150 high vaginal swab samples taken from the infertile females and also 200 high vaginal swab samples of fertile females were analyzed for the presence of M. hominis and U. urealyticum (Table 1). Of the 350 collected samples, 11 samples were positive for M. hominis (3.14%) and 15 samples were positive for U. urealyticum (4.28%). A statistically significant difference was seen between the prevalence of M. hominis and U. urealyticum (P < 0.05). A significant difference was also seen between the type of samples and prevalence of bacteria (P < 0.05). Overall, five out of 350 samples (1.42%) were infected with both M. hominis and U. urealyticum. Samples taken from the high vaginal parts of the infertile females had a higher prevalence of M. hominis and U. urealyticum than those taken from fertile females (P < 0.05). The results of the conventional technique were confirmed using the PCR method. Seasonal distribution of M. hominis and U. urealyticum is shown in Figure 1. Results showed that M. hominis and U. urealyticum had a higher prevalence in the high vaginal samples collected during the summer season, followed by spring and autumn. A statistically significant difference was seen in the prevalence of bacteria between hot and cold seasons of the year (P < 0.05).
Figure 1.

Seasonal Distribution of Mycoplasma hominis and Ureaplasma urealyticum in Fertile and Infertile Females

5. Discussion

The results of our study showed that M. hominis and U. urealyticum had a considerable prevalence in the high vaginal swab samples collected from the infertile females referred to Iranian hospitals and health centers. Our results showed that the prevalence of M. hominis and U. urealyticum in fertile and infertile females were 3.14% and 4.28%, respectively. The prevalence of both bacteria was higher in samples taken from infertile females than those of fertile controls. One possible explanation for the higher prevalence of bacteria in the infertile females is hormonal disorders. In fact, hormonal disorders that occur in infertile females can lead to reduced levels of immunity and increase bacterial colonization and survival in vaginal epithelium (17). A previous study showed that the levels of Igs G, A, M and SIgA, IgA, and lysozyme were decreased in infertile females (18). Pelzer et al. (2011) reported that female follicular fluid is not sterile and the levels of cytokines, chemokines and growth factors, which are essential for ovarian function (18), secretion of ovarian steroid hormones (19) and development and regression of corpus luteum (20), were decreased in follicular fluid of infertile females. In addition to the considerable prevalence of M. hominis and U. urealyticum in high vaginal swab samples of our study, several previously published reports revealed various prevalence rates for these bacteria. Akya et al. (2014) (21) reported that the prevalence of M. hominis and U. urealyticum were 34.9% and 6%, respectively, which was higher than our results. The prevalence rate of M. hominis and U. urealyticum in vaginal swabs ranged from zero to 3.8% (22, 23). The prevalence of U. urealyticum was reported from 20% in South America to 41.9% and 51.5% in Italy and Africa, respectively (22). Zdrodowska-Stefanow et al. (2006) (24) and Rodriguez et al. (2001) (25) reported higher prevalence rates of U. urealyticum infection (37-50%). In keeping with this, the prevalence of these bacteria was lower in some other studies (23, 26). Peerayeh et al. (2007) (27) reported that of the 377 patients studied, 141 samples (37.4%) were positive for U. urealyticum, which was higher than our results. A previous study from Ahvaz, Iran (28) showed that the prevalence of M. hominis and U. urealyticum in the genital samples of females were 6.4% and 13.6%, respectively. They showed that the highest prevalence of M. hominis (54.5%) and U. urealyticum (53.8%) was found in females within 28 - 33 and 34 - 39 years old. Another study from Iran (29) showed that the prevalence of M. hominis from vaginal and cervical parts of 104 patients aged 18 to 48 years were 30% and 21%, respectively, both being higher than our findings. The different prevalence rates reported by previous studies may be due to factors, including the population tested (whether the subjects had received antibiotics, had a genital infection or not, and the number of sexual partners, etc.), type of samples (vaginal swabs, cervical swabs, urine etc.), number of samples collected, methods of sampling, experimental methods, age, socioeconomic status, geographical area, season of sampling and even climate of the sampled area. Our findings also revealed that the majority of bacterial strains were recovered from high vaginal samples collected during the summer season. The main reason for the highest prevalence of M. hominis and U. urealyticum in summer is the fact that during this time climatic events, heat, rain, and thunderstorms, as well as variation of barometric pressure may have an influence on the prevalence of bacteria. Bacteria have higher growth rate and surveillance under warm conditions. After analyzing the average temperatures of the region of sampling (16°C for spring, 31°C for summer, 13°C for autumn and 4°C for winter), it was determined that the prevalence rate of M. hominis and U. urealyticum strains during each season is related to the average temperatures. This study is the first prevalence report of seasonal distribution of M. hominis and U. urealyticum in high vaginal swab samples of infertile females. The present study showed the considerable prevalence of M. hominis and U. urealyticum in high vaginal swab samples of infertile and fertile females from Iran. Considering the high prevalence rate (3.14% for M. hominis and 4.28% for U. urealyticum), there is a need to use a rapid diagnostic method. The PCR technique using the urease gene of the U. urealyticum and 16SrRNA gene of the M. hominis, which was applied in this study, could be used as a safe, sensitive, specific and fast method for diagnosis of M. hominis and U. urealyticum. The authors of the present study recommended precise monitoring and control of fertile and infertile females for the presence of M. hominis and U. urealyticum and treatment of positive cases to prevent infection and possibly infertility.
Table 2.

Prevalence of Mycoplasma hominis and Ureaplasma urealyticum in the High Vaginal Swab Samples of Fertile and Infertile Females

Types of High Vaginal Swab SamplesNo Samples CollectedNo. Bacteria (%)
No. M. hominisNo. U. urealyticumBoth Bacteria
Fertile females 2003 (1.5)5 (2.5)1 (0.5)
Infertile females 1508 (5.33)10 (6.66)4 (2.66)
Total 35011 (3.14)15 (4.28)5 (1.42)
  22 in total

1.  [Genital infection and infertility].

Authors:  R Rodríguez; R Hernández; F Fuster; P Prieto; J Alberto
Journal:  Enferm Infecc Microbiol Clin       Date:  2001 Jun-Jul       Impact factor: 1.731

Review 2.  Mycoplasma genitalium infections. Diagnosis, clinical aspects, and pathogenesis.

Authors:  Jørgen Skov Jensen
Journal:  Dan Med Bull       Date:  2006-02

3.  Prevalence of Chlamydia trachomatis, Mycoplasma hominis, Mycoplasma genitalium, and Ureaplasma urealyticum infections and seminal quality in infertile and fertile men in Kuwait.

Authors:  Noura A Al-Sweih; Amani H Al-Fadli; Alexander E Omu; Vincent O Rotimi
Journal:  J Androl       Date:  2011-11-03

4.  International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care.

Authors:  Jacky Boivin; Laura Bunting; John A Collins; Karl G Nygren
Journal:  Hum Reprod       Date:  2007-03-21       Impact factor: 6.918

5.  Ureaplasma urealyticum and Mycoplasma hominis infection in women with urogenital diseases.

Authors:  B Zdrodowska-Stefanow; W M Kłosowska; I Ostaszewska-Puchalska; V Bułhak-Kozioł; B Kotowicz
Journal:  Adv Med Sci       Date:  2006       Impact factor: 3.287

6.  Expression of FKHR, FKHRL1, and AFX genes in the rodent ovary: evidence for regulation by IGF-I, estrogen, and the gonadotropins.

Authors:  JoAnne S Richards; S C Sharma; Allison E Falender; Yuet H Lo
Journal:  Mol Endocrinol       Date:  2002-03

7.  Evaluation of intraspecies genetic variation within the 16S rRNA gene of Mycoplasma hominis and detection by polymerase chain reaction.

Authors:  A Blanchard; A Yáñez; K Dybvig; H L Watson; G Griffiths; G H Cassell
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

Review 8.  Ureaplasma urealyticum, Mycoplasma hominis and adverse pregnancy outcomes.

Authors:  Romina Capoccia; Gilbert Greub; David Baud
Journal:  Curr Opin Infect Dis       Date:  2013-06       Impact factor: 4.915

9.  Prevalence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum in pregnant women.

Authors:  Mehmet Refik Bayraktar; Ibrahim Halil Ozerol; Nilay Gucluer; Onder Celik
Journal:  Int J Infect Dis       Date:  2009-06-09       Impact factor: 3.623

10.  Prevalence and antimicrobial susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in female outpatients, 2009-2013.

Authors:  Qing-Yong Wang; Rong-Hai Li; Lu-Qing Zheng; Xiao-Hong Shang
Journal:  J Microbiol Immunol Infect       Date:  2014-07-28       Impact factor: 4.399

View more
  5 in total

1.  Detection and Evaluation of Macrolide Resistance (Erythromycin) in Mycoplasma hominis Isolated from Endocervical Specimens of Patients Referring to Ibn Sina Infertility Treatment Centre, Tehran, Iran.

Authors:  Faezeh Nazarzadeh; Mohammad Hossein Ahmadi; Soheila Ansaripour; Mohammad Niakan; Iman Pouladi
Journal:  Int J Fertil Steril       Date:  2022-05-08

2.  'Mycoplasma hominis does not share common risk factors with other genital pathogens': Findings from a South African pregnant cohort.

Authors:  Meleshni Naicker; Fazana Dessai; Ravesh Singh; Nireshni Mitchev; Partson Tinarwo; Nathlee S Abbai
Journal:  S Afr J Infect Dis       Date:  2021-05-19

3.  Effect of Mycoplasma hominis and cytomegalovirus infection on pregnancy outcome: A prospective study of 200 Mongolian women and their newborns.

Authors:  Byambaa Otgonjargala; Kathrin Becker; Gunchin Batbaatar; Sandag Tsogtsaikhan; Jamsranjav Enkhtsetseg; Altangerel Enkhjargal; Klaus Pfeffer; Ortwin Adams; Chimeddorj Battogtokh; Birgit Henrich
Journal:  PLoS One       Date:  2017-03-03       Impact factor: 3.240

4.  Epidemiology of genital infections caused by Mycoplasma hominis, M. genitalium and Ureaplasma urealyticum in Iran; a systematic review and meta-analysis study (2000-2019).

Authors:  Khadijeh Moridi; Mohammad Hemmaty; Amir Azimian; Mohammad Hosein Fallah; Hamid Khaneghahi Abyaneh; Kiarash Ghazvini
Journal:  BMC Public Health       Date:  2020-06-29       Impact factor: 3.295

5.  Mollicutes antibiotic resistance profile and presence of genital abnormalities in couples attending an infertility clinic.

Authors:  Brenda Maldonado-Arriaga; Noé Escobar-Escamilla; Juan Carlos Pérez-Razo; Sofia Lizeth Alcaráz-Estrada; Ignacio Flores-Sánchez; Daniel Moreno-García; Rebeca Pérez-Cabeza de Vaca; Paul Mondragón-Terán; Jonathan Shaw; Cecilia Hernandez-Cortez; Graciela Castro-Escarpulli; Juan Antonio Suárez-Cuenca
Journal:  J Int Med Res       Date:  2019-02-28       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.